|
|
|
|
Process improvements for XOFLX® lentiviral producer cell lines can significantly increase batch yields, helping manufacturers enhance vector production efficiency, scalability, and overall process performance for gene therapy applications.
|
|
|
|
|
Enhanced lentiviral vector productivity accelerated a CAR-T program to IND filing, demonstrating how targeted process optimization can shorten development timelines, increase manufacturing efficiency, and support clinical readiness.
|
|
|
|
|
AAV manufacturing often faces cost and scalability challenges. Learn how a how the TESSA® technology improves yield, streamlines production, reduces complexity, and supports more efficient commercialization of gene therapies.
|
|
|
|
|
Silencing cargo gene expression during lentiviral vector and AAV production can improve vector yield, enhance product purity, reduce manufacturing complexity, minimize production-related challenges, and support more efficient gene therapy development and commercialization.
|
|
|
|
|
|
|
Optimize in-vivo lentiviral CAR-T development with rigorous, GMP-compliant testing. Explore customizable assay panels designed to ensure product safety, accurate dosing, and regulatory alignment.
|
|
|
